|
Proteína C reactiva ultrasensible como biomarcador pronóstico de enfermedad cardiovascular [Ultrasensitive C-reactive protein as a prognostic biomarker for cardiovascular disease] |
Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Urtasun M, Comandé D, Brito V |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Urtasun M, Comandé D, Brito V. Proteína C reactiva ultrasensible como biomarcador pronóstico de enfermedad cardiovascular. [Ultrasensitive C-reactive protein as a prognostic biomarker for cardiovascular disease] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Técnico Breve N° 47. 2013 Authors' objectives To assess the available evidence on the usefulness of ultra-sensitive C-reactive protein as an independent risk factor in the asymptomatic population and as prognostic factor in the population with cardiovascular disease. Authors' conclusions There is large high quality evidence about the usefulness of US-CRP as CVE risk predictor in all the populations assessed. However, despite there is no direct evidence whether the US-CRP determination can improve patient prognosis, there is consensus on the fact that by re-categorizing the risk and altering the therapeutic approaches, there may be benefits for the group of patients without known coronary disease and with intermediate risk of events at 10 years. The existing evidence to date highlights the usefulness of US-CRP at the time of defining statin therapy in men and women without CHD, 50 years old or older and 60 years old respectively, in the presence of LDL-<130 mg/dL levels and no co-morbidities such as diabetes. CRP measurement in men younger than 50 years old and women 60 years of age or younger is considered as a potential additional tool when estimating the individual risk of CVE at10 years. It is not recommended to assess the levels of US-CRP both in asymptomatic individuals at high risk of CVE and in males below 50 years old or women 60 years old or younger at low risk of CVE at 10 years. There is no consensus supporting the usefulness of adding US-CRP to risk staging in patients with stable coronary disease or acute coronary syndrome. Indexing Status Subject indexing assigned by CRD MeSH Biomarkers; C-Reactive Proteins; Cardiovascular Diseases Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32014000252 Date abstract record published 28/01/2014 |
|
|
|